Viewing Study NCT00319631



Ignite Creation Date: 2024-05-05 @ 4:48 PM
Last Modification Date: 2024-10-26 @ 9:24 AM
Study NCT ID: NCT00319631
Status: WITHDRAWN
Last Update Posted: 2017-01-30
First Post: 2006-04-27

Brief Title: Role of Vascular Endothelial Growth Factor VEGF in Acute Lung InjuryAdult Respiratory Distress Syndrome ARDS
Sponsor: Weill Medical College of Cornell University
Organization: Weill Medical College of Cornell University

Study Overview

Official Title: Role of Vascular Endothelial Growth Factor VEGF in Acute Lung InjuryAdult Respiratory Distress Syndrome ARDS
Status: WITHDRAWN
Status Verified Date: 2017-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Under the discretion of the PI the study has been withdrawn
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Understanding the role VEGF plays in ARDS consequently provides an ideal opportunity to discover new therapies for ARDS
Detailed Description: In previous lab experiments we observed evidence of pulmonary edema following alveolar epithelial overexpression of VEGF suggesting a potential role for VEGF in ARDS In addition we found that preventing VEGF from reaching its target receptors by overexpressing a soluble form of a VEGF receptor protein prevents edema formation

These observations heighten the plausibility of VEGF playing an important role in the development of increased pulmonary capillary permeability during acute lung injury Understanding this role VEGF plays in ARDS consequently provides an ideal opportunity to discover new therapies for ARDS

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None